© Reuters.
DUBLIN, Ohio – Cardinal Health (NYSE: NYSE:) has expanded its Board of Directors with the appointment of Robert “Bob” Azelby as an independent director, starting March 1. Azelby, a seasoned executive with over 30 years of experience in the healthcare industry, has held leadership roles including CEO positions at Eliem Therapeutics and Alder BioPharmaceuticals, as well as a Chief Commercial Officer at Juno Therapeutics.
Azelby’s extensive background also encompasses serving on multiple boards within the biopharmaceutical sector, such as ADC Therapeutics and Autolus Therapeutics (NASDAQ:), and his previous roles at companies like Amgen (NASDAQ:). His addition to the Cardinal Health board is seen as a strategic enhancement due to his deep expertise in specialty pharmaceuticals and oncology, areas where Cardinal Health is actively engaged.
Greg Kenny, Chairman of the Board for Cardinal Health, and Jason Hollar, CEO of the company, both expressed their confidence in Azelby’s capabilities to contribute significantly to the board’s guidance of the company’s strategic priorities. Kenny highlighted Azelby’s reputation and leadership in complex organizations, while Hollar emphasized the value of his broad healthcare industry experience.
Cardinal Health, a key player in the distribution of pharmaceuticals and medical products, operates in over 30 countries and employs approximately 48,000 people worldwide. The company is recognized for its extensive history of over 50 years in the healthcare industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
